Related Experiment Videos
[Hexoprenaline tocolysis--side effects in the child?]
Zeitschrift Fur Geburtshilfe Und Perinatologie
|September 1, 1985
Insights
Maternal treatment with Hexoprenaline, a uterine relaxant, showed no adverse effects on infant development. Newborns and three-year-olds exposed to Hexoprenaline exhibited normal health and developmental findings.
Area of Science:
- Obstetrics and Gynecology
- Neonatal Health
- Pediatric Development
Context:
- Maternal use of uterine relaxants during pregnancy.
- Hexoprenaline as a tocolytic agent.
- Assessing infant outcomes following prenatal exposure.
Purpose:
- To evaluate the safety and developmental impact of Hexoprenaline exposure in infants.
- To determine if maternal Hexoprenaline treatment affects early childhood development.
Summary:
- Two groups of children exposed to maternal Hexoprenaline treatment were assessed.
- Examinations included newborns (first week) and three-year-olds.
- Comprehensive assessments covered internistic, neurological, electrocardiogram (EKG), and blood analyses.
Impact:
- No signs of pathological development were observed in either age group.
- All assessed health and developmental parameters were within normal limits.
- Findings suggest Hexoprenaline is safe for fetal development with no discernible negative impacts.
Abstract:
There were examined two groups of children, whose mother were treated with the uterine relaxant Hexoprenalin. 21 children were examined when they were three years of age, 28 children during their first week of live (internistic and neurological findings, EKG and blood-analyses). There were no signes of pathological development; all the findings were within the norm.